Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-centre UK study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Radia Chandni, Danso Yaa, Ritchie Susan, Hale Melissa, Elford Alexander T, Patel Chirag, Hicks Lucy, Kalyanji Sonia, Dong Chaonan, Yeung Katie, Yeo Jie Han, Allah-Ditta Mohammed, Bishara Maria, Sethi-Arora Karishma, Pillay Lushen, Johnston Emma L, Rudling Ruth, Rees Fiona, Harvey Philip, Trodden-Mittnacht Hannah, Davis Emma, Fraser Aileen, Sawan Nitish Jivan, Hussain Muhammad Azhar, Campbell Roisin, George Becky, Rawcliffe Megan, Choon Xin Yi, Shah Krishna, Al-Zarrad Dania, Toft Jennifer, Chhabra Puneet, Burr Nick, Hewitt Alice, Kumar Rohith, McCartney Sara, Rosiou Konstantina, Dhar Anjan, Lees Charlie W, Lamb Christopher A, Speight Ally, Ahmad Tariq, Limdi Jimmy, Raine Tim, Walsh Alissa, Cooney Rachel, Harrow Paul, Patel Kamal, Samaan Mark, Pavlidis Polychronis, Kent Alexandra, Selinger Christian, Kok Klaartje Bel
Аннотация
METHODS: A retrospective multicenter cohort study encompassing 19 UK hospitals was undertaken. Primary outcome was clinical remission (Simple Clinical Colitis Activity Index/partial Mayo Score ≤ 1) at weeks 8 and 24, based on available assessments. Biochemical (CRP ≤ 5mg/L and fecal calprotectin ≤ 200µg/g) and endoscopic (Ulcerative Colitis Endoscopic Index of Severity/Mayo Endoscopic Subscore ≤ 1) remission were also assessed.
RESULTS: A total of 131 patients with active UC were included. The majority (60%) had exposure to ≥3 advanced therapies and 50% required corticosteroids at induction. Clinical remission rates were 59% and 51% at weeks 8 and 24. Biochemical and endoscopic remission rates were 61% and 60% at week 8, and 47% and 32% at week 24. All disease activity parameters significantly reduced by week 8 (P < .001). At week 24 no difference was detected in clinical remission rates between those with primary non-response (42%) or secondary loss of response (52%) to their first JAKi (P = .518). Clinical remission did not differ between upadacitinib (54%) and filgotinib (36%), P = .253. Adverse events occurred in 27% of patients, and serious adverse events in 8%.
CONCLUSIONS: In this highly refractory cohort with active UC a second JAKi effectively achieved remission following IR to first JAKi. Type of first JAKi failure did not appear to influence clinical remission. No new safety signals were found.